{"url_path":"/sec/krro/8-k/2026-05-19/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1703647/0001193125-26-229610-index.html","accession_number":"0001193125-26-229610","cik":"0001703647","ticker":"KRRO","issuer_name":"Korro Bio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1703647/0001193125-26-229610-index.html","primary_entity_key":"0001703647","primary_entity_name":"Korro Bio, Inc."},"word_count":101,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn May 19, 2026, Korro Bio, Inc. issued a press release announcing the addition of KRRO-111 for the potential treatment of Alpha-1 Antitrypsin Deficiency to its pipeline of therapeutic programs in development. A copy of the press release is filed as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.\n\nKorro Bio, Inc. also updated its corporate presentation for use in meetings with investors, analysts and others. A copy of certain updated slides is filed as Exhibit 99.2 to this current report on Form 8-K and is incorporated herein by reference."}